SUPN

NASD Supernus, Inc.
Nov 20, 2026 · 11:23 AM ET DELAYED Market Open

$28.95 ↑ +0.60 (+2.12%) Trading Up from the previous close of $28.35, $0.56 below the day’s high of $29.51

YTD change
-41.75%
vs 20-day SMA
-12.08%
vs 200-day SMA
-36.98%

Price ranges

Previous day
$28.32 $29.37
open $29.11 close $28.35
-$0.76 (-2.61%)
Today
$28.15 $29.51
open $28.39 now $28.95
+$0.56 (+1.97%)
Past week
$28.32 $29.92
from $29.20 now $28.95
-$0.25 (-0.86%)
Past month
$25.92 $44.31
from $41.21 now $28.95
-$12.26 (-29.75%)
This year
$25.92 $59.68
from $49.70 now $28.95
-$20.75 (-41.75%)

Price & Performance

-20.34 (-41.77%) / 6M

$24.22$33.61$42.99$52.38May 20Aug 20Nov 19

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Not So Good
  • The stock is 52.7% away from all-time highs of $61.25
  • SUPN is down 42% since the beginning of the year
  • SUPN is down 35% over the past 12 months
  • SUPN is down 30% over the past 1 month
  • 4% of all SUPN investors are betting against SUPN

SUPN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -36.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $1.32
Earnings momentum -51.8% Quarterly EPS growth
Quarterly change -51.8%

Valuation

P/E ratio N/A
Enterprise value $3.7B
Beta 0.99

Balance sheet & scale

Income$446.9K
Revenue$1.4B
Cash$305.0M
Debt$501.0K
Income / Debt 0.89×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $3.6B

Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,351.12 -2.29%
JNJ Johnson & Johnson $267.14 -2.04%
ABBV AbbVie, Inc. $283.54 -0.86%
RHHVF Roche Holding Ltd $480.00 +0.46%
MRK Merck & Co., Inc. $132.81 -3.61%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.